Aquí es donde compartimos los valiosos conocimientos que hemos aprendido de nuestros años de experiencia en ensayos clínicos descentralizados. Desplázate hacia abajo para ver nuestro contenido más reciente.
Decentralized trials (DCTs) expand older adults’ access to trials, allowing them to participate at higher rates.
Digital transformation is reshaping nearly every industry, and clinical trials are no exception. As technology plays a bigger role in healthcare, patients are demanding more access to medical research. It’s not just patients who are asking for more: Medical professionals, researchers, and pharmaceutical companies all want to improve quality, efficiency, and access to clinical trials.
The use of real world data in clinical trials is a hot topic. Doctors, biotech and pharmaceutical companies alike point to the tremendous potential to leverage this data to improve health outcomes.
Virtual clinical trials aren’t just a buzzword—these research models are here to stay. In fact, the global market for virtual clinical trials is expected to reach $12.9 billion by 2030, according to Grand View Research.
Capturing and assessing patient-reported outcomes is key to driving patient centricity in healthcare research and delivery. However, the life sciences industry has frequently struggled to gather adequate, high-quality participant data in clinical trials, resulting in costly delays for study teams.